WO2023014337 - VIRAL AND HOST BIOMARKERS FOR EARLY DETECTION, THERAPEUTIC EFFECTIVENESS, AND RELAPSE MONITORING OF CANCER LINKED TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 AND HUMAN PAPILLOMA VIRUS
National phase entry is expected:
Publication Number
WO/2023/014337
Publication Date
09.02.2023
International Application No.
PCT/US2021/010031
International Filing Date
04.08.2021
Title **
[English]
VIRAL AND HOST BIOMARKERS FOR EARLY DETECTION, THERAPEUTIC EFFECTIVENESS, AND RELAPSE MONITORING OF CANCER LINKED TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 AND HUMAN PAPILLOMA VIRUS
[French]
BIOMARQUEURS VIRAUX ET DE L'HÔTE POUR LA DÉTECTION PRÉCOCE, L'EFFICACITÉ THÉRAPEUTIQUE ET LA SURVEILLANCE DES RÉCIDIVES DE CANCER LIÉES AU CORONAVIRUS 2 RESPONSABLE DU SYNDROME RESPIRATOIRE AIGU SÉVÈRE ET AU PAPILLOMAVIRUS HUMAIN
Applicants **
GUERRERO-PRESTON, Rafael
Inventors
GUERRERO-PRESTON, Rafael
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Natural Person
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1914 | |
| EPO | Filing, Examination, Granting | 8796 | |
| Japan | Filing, Examination, Granting | 2073 | |
| South Korea | Filing, Examination, Granting | 1725 | |
| USA | Filing, Examination, Granting | 4310 |
Total:
18,818
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention provides methods of detection, including early detection for cancer mediated by SARS-CoV-2 and HPV, by themselves or together with one or more of the following biomarkers: gene specific DNA methylation levels; whole genome DNA methylation levels; host RNA expression levels; T-Cell receptor amount or clonality, and B-Cell receptor amount or clonality. These methods are useful for, among other things, assessing the effectiveness of treatment, monitoring relapse, and clinical staging of cancer. These methods are also useful for among other tilings to monitor the effectiveness of strategies and therapies used to modify lifestyle and contextual effects to prevent disease, foster wellness and enable health promotion.[French]
La présente invention concerne des procédés de détection, y compris la détection précoce d'un cancer médié par le SARS-CoV-2 et le HPV, seuls ou en association avec un ou plusieurs des biomarqueurs suivants : niveaux de méthylation de l'ADN spécifiques des gènes ; niveaux de méthylation de l'ADN du génome entier ; niveaux d'expression de l'ARN de l'hôte ; quantité ou clonalité des récepteurs des lymphocytes T, et quantité ou clonalité des récepteurs des lymphocytes B. Ces procédés sont utiles, entre autres, pour évaluer l'efficacité d'un traitement, surveiller les récidives et la stadification clinique du cancer. Ces procédés sont également utiles pour, entre autres, évaluer l'efficacité des stratégies et des thérapies utilisées pour modifier le mode de vie et les effets contextuels afin de prévenir les maladies, favoriser le bien-être et permettre la promotion de la santé.